CEO Gary Phillips said, “We are confident that these results, if repeated in the whole study population, will satisfy regulatory requirements to continue the development of PXS-5505 in myelofibrosis and also excite clinicians, patients and industry groups who are closely following our progress with this novel mechanism." …
Pharmaxis reports positive interim data from myelofibrosis study
October 20, 2022 BioPharmaAustralian Biotech
Latest Video
New Stories
-
Australia’s life sciences sector emerges as fast growing, globally connected powerhouse
May 21, 2026 - - Latest News -
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 - - Latest News -
New report reveals how AI is now deciding which healthcare brands Australians see online
May 21, 2026 - - Latest News -
Medicine shortages and workforce gaps threaten the sustainability of Australian care
May 21, 2026 - - Latest News -
Sanofi therapy wins Australian registration for non-relapsing secondary progressive MS
May 20, 2026 - - Latest News -
Owen Smith: 'We are ready to negotiate. We are ready to be a genuine partner'
May 19, 2026 - - Latest News -
Australia bets on translational science to turn discovery into global impact
May 19, 2026 - - Latest News